A Prospective, Open-Label, Multicenter Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of Therapure PlasmaCap IG in Adults and Children With Primary Immune Deficiency Diseases

Therapure Biopharma Inc12 sites in 2 countries74 target enrollmentSeptember 5, 2017

ConditionsPrimary Immune Deficiency Diseases (PIDD)

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: Primary Immune Deficiency Diseases (PIDD)
Sponsor: Therapure Biopharma Inc
Enrollment: 74
Locations: 12
Primary Endpoint: Mean acute Serious Bacterial Infection (SBI) rate
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to investigate the efficacy, safety, tolerability, and pharmacokinetic profile of the investigational medicinal product (IMP) and to determine, on the basis of historical control data, how it compares with other 10% intravenous immunoglobulin (IGIV) products currently licensed in North America for the treatment of subjects with primary immune deficiency diseases (PIDD).

Registry

clinicaltrials.gov

Start Date

September 5, 2017

End Date

December 30, 2020

Last Updated

5 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Therapure Biopharma Inc

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Subject has a confirmed clinical diagnosis of a PIDD, which requires treatment with IGIV:
•Subject/guardian has provided written informed consent (and assent, as applicable).
•Subject is between the ages of 2 and 70 years.
•Subject has received regular IGIV therapy at 21- or 28-day (±4 days) intervals for at least three consecutive months at a dose between 300-900 mg/kg/month prior to Screening or;
•Subject has received commercial SCIG at a dose of 300-900 mg/kg/month on any dosing schedule for at least 12 consecutive weeks prior to Screening. Subjects on SCIG must have received and tolerated IGIV treatment prior to SCIG treatment.
•Subject has a documented trough of ≥500 mg/dL in the 6 months prior to screening.
•Females of childbearing potential must be willing to use an effective form of birth control (eg, oral contraceptives) for the duration of the study, per IRB/REB guidelines.
•Subject agrees to comply with the requirements of the protocol.

Exclusion Criteria

•Subject has secondary immunodeficiency.
•Subject has history of thrombotic events, such as deep vein thrombosis, myocardial infarction, cerebrovascular accident, pulmonary embolism, etc within the year prior to screening.
•Subject has had an immune globulin associated arterial or venous thrombotic/thromboembolic event (TEE) within 7 days of infusion or a TEE that is not associated with an immune globulin within one year of screening.
•Subject has received blood products (except for IGIV, SCIG, or albumin) within 6 months of screening.
•Subject has anemia (≤8.5 g/dL).
•Subject has levels of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>3.0 times the upper limit of normal (ULN).
•Subject has severe neutropenia (≤1000 neutrophils per mm3).
•Subject is receiving other immunosuppressive or immunomodulatory drugs or chemotherapy.
•Subject is taking or has taken within the four weeks prior to screening prednisone at ≥0.15 mg/kg/day for more than 10 days.
•Subject has ever had a severe anaphylactic reaction to a blood or IgG product.

Outcomes

Primary Outcomes

Mean acute Serious Bacterial Infection (SBI) rate

Time Frame: 1 year

The primary efficacy objective of the study is to demonstrate the efficacy of the IMP by determining that the mean annual acute SBI rate (as defined in Appendix 20.1) is statistically significantly lower than one infection per subject per year.